Figure 5

Recombinant IL-37 decreases pro-inflammatory cytokines productions in PBMCs of AS patients. PBMCs from AS patients (n = 46) and HC (n = 35) were stimulated with or without IL-37 (100 ng/ml) for 6 h, cells then cultured with LPS (1 ug/ml) for 4 h, the total RNAs were extracted and analyzed for TNF-α (A), IL-6 (B) IL-23 (C) and IL-17 (D) mRNAs by RT-PCR. PBMCs from AS patients (n = 46) and HC (n = 35) were stimulated with or without IL-37 (100 ng/ml) for 24 h and then incubated further with LPS (1 μg/ml) for 8 h, supernatants of the cells were examined for TNF-α (E), IL-6 (F), IL-23 (G) and IL-17 (H) protein levels using ELISA. Results are expressed as mean ± SEM, P < 0.05 represents a significant difference. AS + IL-37, PBMCs from AS stimulated with the recombinant IL-37; HC + 37, PBMCs from HC stimulated with the recombinant IL-37; NS, not significant; *P < 0.05; **P < 0.01.